Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to its Board of Directors

CANTON, MA, United States, via ETELIGIS INC., 02/09/2015 – – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced today the appointments of Paul Brannelly as Executive Vice President and Chief Financial Officer and Garen Bohlin to its Board of Directors, effective immediately.

“Adding Paul to Collegium’s management team and Garen to our Board of Directors comes at a critical time as we advance our lead abuse-deterrent development program through the NDA review process,” said Michael Heffernan, President and CEO. “Both Paul and Garen’s significant experience in building both public and private life sciences companies will be invaluable as we plan for significant company growth upon FDA approval of XTAMPZA ER™.”

Paul Brannelly, Chief Financial Officer:

Paul has held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded specialty pharmaceutical company. Prior to joining Karyopharm, he held the position of Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly held biotechnology company. Prior to Verastem, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund. Paul also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With over 15 years in the biopharmaceutical industry, Paul has raised more than $700 million in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.

Garen Bohlin, Board Member:

Garen held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Garen was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline. Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals, which was acquired by Biogen Idec. Prior to Syntonix, he was Executive Vice President of Genetics Institute, which was acquired by American Home Products/Wyeth. Garen played a key strategic role in each of his positions and also had substantial operational experience. Mr. Bohlin currently serves on the board of directors of Karyopharm Therapeutics Inc., Proteon Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. and previously served as a director on the boards of five other companies.

About DETERx Technology:

The DETERx® drug delivery platform consists of a microsphere-in-capsule formulation. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation, and extraction for IV injection, the microsphere design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents onto food or via feeding tube, while maintaining the ER properties of the product. The DETERx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. XTAMPZA ER™ (oxycodone extended-release capsules) is the first of a number of product candidates using the DETERx platform.

About Collegium Pharmaceutical, Inc.:

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx formulation platform for the treatment of chronic pain. The DETERx oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company’s website at


Douglas R. Carlson

Vice President, Corporate Development

Collegium Pharmaceutical, Inc.



SOURCE: Collegium Pharmaceutical, Inc.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s